Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
d development of pharmaceuticals anduncertainties related to the regulatory process. Investors should consultthe Company's quarterly and annual filings with the Canadian and U.S.securities commissions for additional information on risks anduncertainties relating to the forward-looking statements. Investors arecautioned against placing undue reliance on forward-looking statements. TheCompany
Date:10/23/2007